Home > Oncology > WCLC 2018 > Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

The multinational, phase 3 JAVELIN Lung 200 trial investigated the PD-L1 antibody avelumab vs docetaxel in patients with advanced NSCLC after failure of platinum-based treatment. Outcomes showed that avelumab had a favourable safety profile but did not improve OS in patients with platinum-treated PD-L1 positive NSCLC. Eligible patients were ≥18 years old and had stage 3B/4 or recurrent NSCLC with disease progression after platinum doublet therapy. Between April 2015 and February 2017, 792 patients were randomised to avelumab (10 mg/kg Q2W) or docetaxel (75 mg/m2 Q3W). Randomisation was stratified by PD-L1 status (PD-L1+/PD-L1-) and histology (squamous/non-squamous).

Of these patients, 264 in the avelumab arm and 265 in in the docetaxel arm had PD-L1+ tumours. In this group, there was no significant difference in median OS between the treatment arms (11.4 vs 10.3 months; HR 0.90; one-sided P=0.16). OS findings may have been confounded by subsequent checkpoint inhibitor ther...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on